吡非尼酮与尼达尼布治疗肺纤维化的临床实践耐受性及药物不良反应
该回顾性研究纳入2014年9月至2016年2月接受吡非尼酮或尼达尼布治疗的肺纤维化患者186例(吡非尼酮129例,尼达尼布57例),评估真实世界耐受性。结果显示因不良事件停药率分别为20.9%和26.3%,与大型临床试验无显著差异,尽管患者基线呼吸功能损害更重且合并症多。
要点
- 真实世界肺纤维化患者使用吡非尼酮或尼达尼布因不良事件停药率与临床试验相当。
- 吡非尼酮常见不良事件为恶心、皮疹/光敏反应和消化不良/GERD。
- 尼达尼布最常见不良事件为腹泻和恶心。
核心结论
- 真实临床实践中肺纤维化患者对尼达尼布或吡非尼酮的耐受性和不良事件谱与临床试验受试者相当。
研究设计与样本
- 回顾性病历审查研究,纳入2014年9月至2016年2月接受吡非尼酮或尼达尼布治疗的肺纤维化患者186例,其中吡非尼酮129例,尼达尼布57例。
- 吡非尼酮平均观察52±17周,尼达尼布平均观察41±15周。
主要发现
- 基线时63%患者需家庭氧疗,平均DLCO为预计值的36±14%。
- 因不良事件停药在吡非尼酮组为20.9%,尼达尼布组为26.3%。
- 吡非尼酮组最常见不良事件为恶心(26.4%)、皮疹/光敏反应(14.7%)和消化不良/GERD(12.4%)。
- 尼达尼布组最常见不良事件为腹泻(52.6%)和恶心(29.8%)。
临床怎么用
- 在合并症多、呼吸功能损害重的真实世界肺纤维化患者中,吡非尼酮和尼达尼布的耐受性与临床试验相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The real-world tolerability of pirfenidone and nintedanib in non-clinical trial patients is unknown. Many patients with pulmonary fibrosis have significant medical co-morbidities or baseline characteristics that exclude them from clinical trial participation. METHODS: We conducted a retrospective chart review study on subjects prescribed nintedanib or pirfenidone for pulmonary fibrosis treatment (any aetiology) from September 2014 to February 2016. A total of 186 subjects were included: 129 received pirfenidone and 57 were prescribed nintedanib and followed up for mean observation periods of 52 ± 17 weeks for pirfenidone and 41 ± 15 weeks for nintedanib. The primary outcome was drug discontinuation as a result of an adverse event. RESULTS: Subjects had significant respiratory impairment at baseline, 63% required home oxygen therapy and mean diffusion capacity of carbon monoxide (DLCO) was 36 ± 14% predicted. Drug discontinuation as a result of an adverse event occurred in 20.9% of subjects on pirfenidone and 26.3% on nintedanib. Drug discontinuation rates for both pirfenidone and nintedanib did not significantly differ from corresponding large clinical trials (ASCEND/CAPACITY and INPULSIS 1 and 2, respectively). Adverse events that occurred with highest frequency on pirfenidone were nausea (26.4%), rash/photosensitivity (14.7%) and dyspepsia/gastroesophageal reflux disease (GERD) (12.4%). Diarrhoea (52.6%) and nausea (29.8%) were reported most often with nintedanib therapy. CONCLUSION: Patients with pulmonary fibrosis treated with nintedanib or pirfenidone in routine clinical practice had drug tolerability and adverse event profiles comparable with subjects enrolled in clinical trials despite having a greater degree of respiratory impairment and a high prevalence of co-morbid medical conditions.
引用
- Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology. 2017. PMID: 28317233. doi:10.1111/resp.13024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。